[PARADIGM SHIFTS IN DIAGNOSIS AND MANAGEMENT OF LOCALIZED PROSTATE CANCER IN 2022].
- Resource Type
- Academic Journal
- Authors
- Laufer M; Department of Urology, Chaim Sheba Medical Center.
- Source
- Publisher: Israel Medical Association Country of Publication: Israel NLM ID: 0034351 Publication Model: Print Cited Medium: Print ISSN: 0017-7768 (Print) Linking ISSN: 00177768 NLM ISO Abbreviation: Harefuah Subsets: MEDLINE
- Subject
- Language
- Hebrew
- ISSN
- 0017-7768
Introduction: In recent years, we witnessed significant changes in the way we diagnose prostate cancer and the options for management of low risk localized prostate cancer. This review discusses today's approach to men with elevated PSA. The use of biomarkers and or prostate MRI is strongly recommended prior to the decision on a biopsy. Following a suspicious finding in MRI the best approach is MRI-guided biopsy. Traditionally, biopsies are performed transrectally but the emerging transperineal biopsy has considerable advantage. With a new diagnosis of low risk prostate cancer, each man should have a lengthy discussion with his urologist and in many cases the preferred way is to proceed with active surveillance and avoid radical treatment.